AP-PA02
Pseudomonas aeruginosa infections in cystic fibrosis
Key Facts
About Armata Pharmaceuticals
Armata Pharmaceuticals is a clinical-stage biotech focused on developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant infections, a critical global health threat. The company's core strategy is built on a vertically integrated platform that spans from natural phage discovery and synthetic engineering to in-house cGMP manufacturing and clinical development. Its lead programs target high-mortality infections like Pseudomonas aeruginosa in cystic fibrosis and Staphylococcus aureus bacteremia, aiming to provide a precise alternative to broad-spectrum antibiotics. Armata's fully controlled 56,000 sq. ft. facility in Los Angeles provides a strategic advantage in developing these complex biologic products.
View full company profileTherapeutic Areas
Other Pseudomonas aeruginosa infections in cystic fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| CSA-131 (Kinnear Pharma) | N8 Medical | Pre-clinical/Research |